Mutual recognition in the European system: A blueprint for increasing access to medicines?
Authors:
Open Access
- 7 May 2019
- journal article
- editorial
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 106, 270-277
Abstract
No abstract availableKeywords
Funding Information
- German Federal Ministry of Health′s Global Health Protection Programme (323-123002)
This publication has 12 references indexed in Scilit:
- Structured Benefit-Risk Assessment Across the Product Lifecycle: Practical ConsiderationsTherapeutic Innovation & Regulatory Science, 2017
- Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market AuthorizationPLOS ONE, 2016
- UK medicines regulation: responding to current challengesBritish Journal of Clinical Pharmacology, 2016
- Supporting the production of pharmaceuticals in AfricaBulletin of the World Health Organization, 2015
- Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in EuropeJournal of Personalized Medicine, 2015
- Future of the European Union regulatory network in the context of the uptake of new medicinesBritish Journal of Clinical Pharmacology, 2012
- Biotechnological products in Pan American Health Organization (PAHO): Regional efforts towards harmonization of regulationBiologicals, 2011
- Granting marketing authorisation for medicines in South East European countries: The point of view of the authorityRegulatory Toxicology and Pharmacology, 2010
- Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemmaNature Reviews Drug Discovery, 2008
- Patient access to pharmaceuticals: an international comparisonThe European Journal of Health Economics, 2007